Form 4: IO Biotech Executive Acquires 215,000 Stock Options
SEC Form 4 Filing
Qasim Iftikhar Ahmad, Chief Medical Officer of IO Biotech, Inc., reports the acquisition of 215,000 stock options.
Summary
- On April 2, 2025, Qasim Iftikhar Ahmad, the Chief Medical Officer of IO Biotech, Inc., acquired 215,000 stock options with an exercise price of $1.07.
- The options vest over time, with one-fourth vesting on April 2, 2026, and the remainder vesting monthly thereafter, contingent upon continued service.
- The vesting schedule includes acceleration clauses upon certain termination events.
Sentiment
Score: 7
Explanation: The document indicates a standard executive compensation practice, suggesting stability and alignment of interests. The sentiment is neutral to positive.
Positives
- The acquisition of stock options by a key executive could signal confidence in the company's future performance.
Future Outlook
The vesting schedule and acceleration clauses suggest a long-term commitment from the executive and alignment with company performance.
Industry Context
Stock option grants are a common practice in the biotech industry to incentivize and retain key executives.
Stakeholder Impact
- The granting of stock options aligns the executive's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 04/02/2025 | Date of transaction: Qasim Iftikhar Ahmad acquired 215,000 stock options. |
| 04/02/2026 | One-fourth of the acquired stock options vest. |
| 04/02/2035 | Expiration date of the stock options. |
Keywords
IO Biotech, Stock Options, Form 4, Executive Compensation, Qasim Iftikhar Ahmad, Chief Medical Officer, Vesting, Equity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.